Aurinia announces additional analysis of its AURORA 1 phase III study data for lupus nephritis presented at ERA-EDTA 2021 congress

The presentation follows the recent introduction of new data from an interim analysis of the AURORA 2 continuation study at the European Alliance of Associations for Rheumatology (EULAR) 2021 Congress. In the assessment presented at ERA-EDTA, researchers conducted a sensitivity study evaluating renal response (RR) with additional urine protein creatinine ratio (UPCR) targets given the efficacy demonstrated of voclosporin in terms of proteinuria reduction in the AURORA 1 study. This examination demonstrated that patients treated with voclosporin in addition to mycophenolate mofetil (MMF) and low-dose steroids achieved statistically significant increased renal response rates regardless of the level of UPCR, including at an even more stringent ?0.3 mg/mg target. The data further support the efficacy and safety observed with voclosporin in the Phase III AURORA 1 trial for lupus nephritis.